MedTrace Logo

HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours

NCT04914351 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2024-03-13

No results posted yet for this study

Summary

This is a Phase I, first-in-human trial to evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY-0102 administered intravenously (IV) once every two weeks in adult patients with locally advanced/metastatic malignant solid tumors.

Conditions

  • Locally Advanced/Metastatic Solid Tumors

Interventions

DRUG

HY-0102

Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle

Sponsors & Collaborators

  • Shanghai HyaMab Biotech Co.,Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-03
Primary Completion
2023-11-27
Completion
2023-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04914351 on ClinicalTrials.gov